Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM

NCT05697510 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Siltuximab

Sponsor

Nantes University Hospital